Durable Protection after Anti-SARS-CoV-2 Monoclonal Antibody Therapy.
作者信息
Misch Elizabeth A
机构信息
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
出版信息
Kidney360. 2022 Jan 27;3(1):8-10. doi: 10.34067/KID.0007722021.
Abstract
摘要
相似文献
1
Durable Protection after Anti-SARS-CoV-2 Monoclonal Antibody Therapy.
Kidney360. 2022 Jan 27;3(1):8-10. doi: 10.34067/KID.0007722021.
2
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
3
Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19.
Viruses. 2023 May 31;15(6):1297. doi: 10.3390/v15061297.
4
Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18. doi: 10.12932/AP-200220-0773.
5
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
6
A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants.
Clin Immunol. 2024 Mar;260:109902. doi: 10.1016/j.clim.2024.109902. Epub 2024 Jan 11.
7
COVID-19 Antibody Trials Have Begun.
JAMA. 2020 Jul 14;324(2):128. doi: 10.1001/jama.2020.11582.
8
Neutralizing monoclonal antibodies for treatment of COVID-19.
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
9
Inhalable neutralizing antibodies - promising approach to combating respiratory viral infections.
Trends Pharmacol Sci. 2023 Feb;44(2):85-97. doi: 10.1016/j.tips.2022.11.006. Epub 2022 Dec 22.
10
COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
Front Immunol. 2020 May 29;11:1196. doi: 10.3389/fimmu.2020.01196. eCollection 2020.
本文引用的文献
1
SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Kidney360. 2021 Oct 20;3(1):133-143. doi: 10.34067/KID.0005732021. eCollection 2022 Jan 27.
2
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
Transpl Infect Dis. 2022 Feb;24(1):e13759. doi: 10.1111/tid.13759. Epub 2021 Dec 7.
3
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.
JAMA. 2021 Nov 23;326(20):2043-2054. doi: 10.1001/jama.2021.19499.
4
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
5
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.
Open Forum Infect Dis. 2021 Jun 7;8(6):ofab255. doi: 10.1093/ofid/ofab255. eCollection 2021 Jun.
6
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med. 2021 Dec 2;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29.
7
Racial and Ethnic Disparities in SARS-CoV-2 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort.
Am J Prev Med. 2021 Nov;61(5):644-651. doi: 10.1016/j.amepre.2021.05.015. Epub 2021 Jul 16.
8
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.
9
Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients.
Transpl Infect Dis. 2021 Oct;23(5):e13705. doi: 10.1111/tid.13705. Epub 2021 Aug 3.
10
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14.
Zotero 插件